Pharmacological characterization of SAGE‐718, a novel positive allosteric modulator of N‐methyl‐<scp>d</scp>‐aspartate receptors

Abstract

These findings provide strong evidence that SAGE-718 is a neuroactive steroid NMDA receptor PAM with a mechanism that is well suited as a treatment for conditions associated with NMDA receptor hypofunction.